Cargando…
Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study
Data on use of monoclonal antibodies (mAbs) in hospitalized patients are limited. In this cross-sectional study, we evaluated the use of mAbs for early treatment of unvaccinated hospitalized patients with mild-to-moderate COVID-19. All inpatients at our center were screened on 27 October 2021. Prima...
Autores principales: | Ong, Sean W. X., Ren, Dongdong, Lee, Pei Hua, Sutjipto, Stephanie, Dugan, Christopher, Khoo, Bo Yan, Tay, Jun Xin, Vasoo, Shawn, Young, Barnaby E., Lye, David C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944709/ https://www.ncbi.nlm.nih.gov/pubmed/35326808 http://dx.doi.org/10.3390/antibiotics11030345 |
Ejemplares similares
-
External validation of the PRIORITY model in predicting COVID-19 critical illness in vaccinated and unvaccinated patients
por: Ong, Sean Wei Xiang, et al.
Publicado: (2022) -
Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
por: Birk, Navina K, et al.
Publicado: (2022) -
1145. Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 in the US
por: Cheng, Mindy M, et al.
Publicado: (2022) -
Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalisations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5 and XBB transmission
por: Wee, Liang En, et al.
Publicado: (2023) -
Sotrovimab for COVID-19
Publicado: (2021)